<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02330965</url>
  </required_header>
  <id_info>
    <org_study_id>DAIT AMS04</org_study_id>
    <nct_id>NCT02330965</nct_id>
  </id_info>
  <brief_title>Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis</brief_title>
  <official_title>Mechanistic Studies of Phase III Trial With BAF312 in Secondary Progressive Multiple Sclerosis (AMS04)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Autoimmunity Centers of Excellence</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary goal of this study is to evaluate the effects of BAF312 (siponimod) on select
      immune and neuronal (nerve) cells by examining laboratory specimens (blood and/or spinal
      fluid) at multiple time points, prior to, and following the initiation of BAF312 or placebo
      treatment, in patients with Secondary Progressive Multiple Sclerosis (SPMS) who are enrolled
      in a clinical trial (NCT01665144) to evaluate the effectiveness and safety of BAF312.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is complementary to a multi-center, randomized, double-blind,parallel-group,
      placebo-controlled, variable treatment duration study comparing the efficacy and safety of
      BAF312 to placebo in patients with SPMS (NCT01665144). Investigators will explore both
      immunological and neuroprotective mechanisms of BAF312 (siponimod), a novel agent in the
      setting of a SPMS clinical trial.

      This study is part of a multi-center study, with the University of Michigan serving as the
      central site.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">July 12, 2017</completion_date>
  <primary_completion_date type="Actual">July 12, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of MBP-reactive Th17 cells</measure>
    <time_frame>From baseline to the follow-up time points (Open label phase + 6 months and OLP +12 months).</time_frame>
    <description>Evaluation (BAF312 versus placebo) of dominant cytokines produced by myelin basic protein (MBP)-stimulated peripheral blood mononuclear cells (PBMCs), measured by ELISpot.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in frequency of polyclonal CD4+ Th17, Th1, Th2, and Treg cells</measure>
    <time_frame>From baseline to the follow-up time points (Open label phase + 6 months and OLP +12 months).</time_frame>
    <description>Compare BAF312 and Placebo (Control) Groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in chemokine and cytokines levels</measure>
    <time_frame>From baseline to the follow-up time points (Open label phase + 6 months and OLP +12 months).</time_frame>
    <description>Compare BAF312 and Placebo (Control) Groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Regulatory B Cells</measure>
    <time_frame>From baseline to the follow-up time points (Open label phase + 6 months and OLP +12 months).</time_frame>
    <description>Compare BAF312 and Placebo (Control) Groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes of clinical status and lymphocyte subgroups</measure>
    <time_frame>From baseline to the follow-up time points (Open label phase + 6 months and OLP +12 months).</time_frame>
    <description>Compare BAF312 and Placebo (Control) Groups</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">40</enrollment>
  <condition>Secondary Progressive Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Subjects Assigned to BAF312</arm_group_label>
    <description>Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive BAF312 (siponimod). Refer to ClinicalTrials.gov record NCT01665144 for more information.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjects Assigned to Placebo (Controls)</arm_group_label>
    <description>Patients with secondary progressive multiple sclerosis (SPMS) randomized to receive placebo. Refer to ClinicalTrials.gov record NCT01665144 for more information.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood Draw</intervention_name>
    <description>Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.</description>
    <arm_group_label>Subjects Assigned to BAF312</arm_group_label>
    <arm_group_label>Subjects Assigned to Placebo (Controls)</arm_group_label>
    <other_name>Phlebotomy</other_name>
    <other_name>Venipuncture</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CSF collection by lumbar puncture (Optional)</intervention_name>
    <description>For participants who volunteer to donate CSF samples: up to 25 mLs (&lt;2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.</description>
    <arm_group_label>Subjects Assigned to BAF312</arm_group_label>
    <arm_group_label>Subjects Assigned to Placebo (Controls)</arm_group_label>
    <other_name>CSF by LP</other_name>
    <other_name>cerebrospinal fluid collected by lumbar puncture</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood &amp; Cerebrospinal Fluid Samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Ambulatory participants with Secondary Progressive Multiple Sclerosis (SPMS) enrolled in
        the EXPAND trial (BAF312 treated and placebo [control] participants) may be enrolled in
        this study after the EXPAND baseline visit has occurred provided that the subject has not
        passed the Month 12 time point.

        -Refer to ClinicalTrials.gov record NCT01665144.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participants enrolled in the multicenter, randomized, double-blind, parallel-group,
             placebo-controlled, variable treatment duration study comparing the efficacy and
             safety of BAF312 to placebo in patients with Secondary Progressive Multiple Sclerosis
             (SPMS) Protocol No. CBAF312A2304 (sponsored by Novartis). Refer to ClinicalTrials.gov
             record NCT01665144.

          -  Subjects enrolled at one of the participating AMS04 study sites located in the United
             States.

          -  Subject must be able to provide written informed consent.

        Exclusion Criteria:

          -  Subjects with severe bleeding disorders, platelet count less than
             (&lt;)50,000/microliters (Î¼L), and/or who are currently on full anticoagulant therapy
             will be excluded from the optional CSF collections.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yang Mao-Draayer, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Multiple Sclerosis Center - University of Michigan Health System</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Fox, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Division of Rheumatology - University of Michigan Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jordan Research &amp; Education Institute: Sutter Alta Bates Summit</name>
      <address>
        <city>Berkeley</city>
        <state>California</state>
        <zip>94705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of California, Davis</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan Health System -Multiple Sclerosis Center</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minneapolis Clinic of Neurology</name>
      <address>
        <city>Golden Valley</city>
        <state>Minnesota</state>
        <zip>55422</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of New Mexico: Health Sciences Center</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Shore Neurologic Associates - Multiple Sclerosis Care Center</name>
      <address>
        <city>Patchogue</city>
        <state>New York</state>
        <zip>11772</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center (CMC)</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic: Mellen Center for Multiple Sclerosis</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Multiple Sclerosis Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Swedish Neuroscience Institute</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98122</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute of Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/about/dait</url>
    <description>Division of Allergy, Immunology, and Transplantation (DAIT)</description>
  </link>
  <link>
    <url>http://clinicaltrials.gov/ct2/show/record/NCT01665144?term=BAF312&amp;rank=4</url>
    <description>Relevant Clinical Trials.gov Record: NCT01665144</description>
  </link>
  <link>
    <url>http://www.autoimmunitycenters.org/mission.php</url>
    <description>Autoimmunity Centers of Excellence (ACE)</description>
  </link>
  <verification_date>November 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2014</study_first_submitted>
  <study_first_submitted_qc>December 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 5, 2015</study_first_posted>
  <last_update_submitted>November 3, 2017</last_update_submitted>
  <last_update_submitted_qc>November 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>clinical research</keyword>
  <keyword>mechanistic studies</keyword>
  <keyword>blood draw</keyword>
  <keyword>CSF by lumbar puncture (optional)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

